A
21.92
-1.29 (-5.54%)
| Previous Close | 23.20 |
| Open | 22.80 |
| Volume | 1,933,932 |
| Avg. Volume (3M) | 2,695,922 |
| Market Cap | 2,772,800,256 |
| Price / Earnings (TTM) | 60.88 |
| Price / Earnings (Forward) | 46.30 |
| Price / Sales | 3.45 |
| Price / Book | 8.61 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -28.83% |
| Operating Margin (TTM) | -49.96% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | -3.20% |
| Total Debt/Equity (MRQ) | 285.94% |
| Current Ratio (MRQ) | 4.08 |
| Operating Cash Flow (TTM) | -8.29 M |
| Levered Free Cash Flow (TTM) | 45.63 M |
| Return on Assets (TTM) | -14.20% |
| Return on Equity (TTM) | -103.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Apellis Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.60 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.69% |
| % Held by Institutions | 104.60% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Baird, 137.28%) | Buy |
| Median | 40.50 (84.81%) | |
| Low | 19.00 (Mizuho, -13.30%) | Hold |
| Average | 38.50 (75.68%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 22.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 13 Jan 2026 | 35.00 (59.71%) | Buy | 22.72 |
| Needham | 13 Jan 2026 | 28.00 (27.77%) | Buy | 22.72 |
| Stifel | 19 Dec 2025 | 48.00 (119.03%) | Buy | 24.65 |
| JP Morgan | 05 Nov 2025 | 36.00 (64.27%) | Buy | 19.95 |
| Mizuho | 03 Nov 2025 | 19.00 (-13.30%) | Hold | 20.69 |
| Baird | 31 Oct 2025 | 52.00 (137.28%) | Buy | 21.47 |
| Citigroup | 31 Oct 2025 | 45.00 (105.34%) | Buy | 21.47 |
| HC Wainwright & Co. | 31 Oct 2025 | 45.00 (105.34%) | Buy | 21.47 |
| TD Cowen | 31 Oct 2025 | 45.00 (105.34%) | Buy | 21.47 |
| Wells Fargo | 15 Oct 2025 | 32.00 (46.02%) | Buy | 25.22 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAUMAL CAROLINE | - | 24.87 | -3,020 | -75,107 |
| CHAN GERALD | 25.12 | - | 7,961 | 199,980 |
| DUNLOP A. SINCLAIR | 25.12 | - | 7,961 | 199,980 |
| FONTEYNE PAUL R. | 25.12 | - | 7,961 | 199,980 |
| MACHIELS ALEC | 25.12 | - | 7,961 | 199,980 |
| O'BRIEN STEPHANIE MONAGHAN | 25.12 | - | 7,961 | 199,980 |
| WALBERT KELI | 25.12 | - | 7,961 | 199,980 |
| WHEELER CRAIG A | 25.12 | - | 7,961 | 199,980 |
| Aggregate Net Quantity | 52,707 | |||
| Aggregate Net Value ($) | 1,324,755 | |||
| Aggregate Avg. Buy ($) | 25.12 | |||
| Aggregate Avg. Sell ($) | 24.87 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BAUMAL CAROLINE | Officer | 05 Jan 2026 | Sell (-) | 3,020 | 24.87 | 75,107 |
| WHEELER CRAIG A | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| WALBERT KELI | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| FONTEYNE PAUL R. | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| O'BRIEN STEPHANIE MONAGHAN | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| CHAN GERALD | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| DUNLOP A. SINCLAIR | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
| MACHIELS ALEC | Director | 01 Jan 2026 | Acquired (+) | 7,961 | 25.12 | 199,980 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |